MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 37.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 159,165 shares of the company's stock after purchasing an additional 42,950 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.13% of 10x Genomics worth $2,286,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Invenomic Capital Management LP bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $2,717,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $450,000. Gotham Asset Management LLC bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $264,000. FORA Capital LLC bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $354,000. Finally, Deutsche Bank AG boosted its position in shares of 10x Genomics by 35.3% during the fourth quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after purchasing an additional 2,657 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,485 shares of the stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total value of $62,125.50. Following the transaction, the insider now owns 448,374 shares of the company's stock, valued at approximately $3,721,504.20. This represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Taich sold 4,044 shares of the stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $33,565.20. Following the completion of the transaction, the chief financial officer now directly owns 331,588 shares in the company, valued at approximately $2,752,180.40. This represents a 1.20% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,872 shares of company stock valued at $173,238. 9.39% of the stock is owned by company insiders.

10x Genomics Stock Performance

Shares of NASDAQ:TXG traded up $0.42 during midday trading on Tuesday, reaching $8.59. 2,653,754 shares of the company's stock traded hands, compared to its average volume of 2,390,875. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -5.65 and a beta of 1.94. 10x Genomics, Inc. has a one year low of $6.78 and a one year high of $24.76. The stock has a 50 day moving average of $8.52 and a 200 day moving average of $11.95.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. The firm had revenue of $154.88 million for the quarter, compared to the consensus estimate of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The company's quarterly revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.50) earnings per share. Sell-side analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TXG has been the topic of several research reports. Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday. Morgan Stanley cut their target price on 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Stifel Nicolaus cut their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, Stephens reissued an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and an average target price of $15.81.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.